Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

These weight loss medications, administered via injections, work by mimicking a hormone called GLP-1, which helps regulate appetite and blood sugar levels.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans. © 2024 Fortune Media IP Limited. All Rights ...

Now, a new study finds that Ozempic, along with similar drugs such as Wegovy, has had a broad “economic and societal impact” because of “noticeable shifts in dietary behavior.” The study ...

More and more people are taking weight loss injectables like Wegovy and Mounjaro — and though the drugs are gaining credibility when used properly, pharmacy experts are worried that not everyone ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...